Exact Sciences Corporation (EXAs): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução da oncologia de precisão, a Exact Sciences Corporation (EXAs) surge como uma força transformadora, pioneira em tecnologias de triagem de câncer não invasivas que estão reformulando como detectamos e entendemos o câncer. Ao alavancar inovações de diagnóstico molecular de ponta, a empresa desenvolveu um modelo de negócios robusto que não apenas aborda os desafios críticos da saúde, mas também cria um valor substancial para pacientes, provedores e partes interessadas em todo o ecossistema médico. Sua abordagem estratégica combina pesquisas científicas avançadas, capacidades sofisticadas de diagnóstico e uma visão centrada no paciente que promete revolucionar a detecção precoce do câncer e insights médicos personalizados.

Exact Sciences Corporation (EXAs) - Modelo de Negócios: Principais Parcerias

Provedores de saúde e hospitais

Ciências exatas mantém parcerias estratégicas com:

• Mayo Clinic (colaboração de pesquisa de longa data)
• Universidade Johns Hopkins
• Clínica de Cleveland

Parceiro	Foco em parceria	Ano estabelecido
Clínica Mayo	Pesquisa de triagem de câncer colorretal	2009
Johns Hopkins	Desenvolvimento de testes de diagnóstico	2014

Companhias de seguros e pagadores

As principais parcerias de seguro incluem:

• UnitedHealthcare
• Aetna
• Cigna

Provedor de seguros	Status de cobertura	Taxa de reembolso
UnitedHealthcare	Cobertura completa de cologuardas	US $ 511 por teste
Cigna	Cobertura abrangente de triagem	US $ 492 por teste

Redes de laboratório e centros de diagnóstico

As redes de colaboração incluem:

• Diagnostics de missão
• Labcorp

Instituições de pesquisa farmacêutica

Colaborações de pesquisa com:

• Instituto Nacional do Câncer
• American Cancer Society
• Instituto de Câncer Dana-Farber

Fornecedores de tecnologia médica e equipamentos

Parcerias de tecnologia com:

• Ilumina
• Thermo Fisher Scientific

Parceiro de tecnologia	Contribuição tecnológica	Valor da parceria
Ilumina	Tecnologia de sequenciamento genético	US $ 37,5 milhões em investimento
Thermo Fisher	Equipamento de diagnóstico	US $ 22,3 milhões de colaboração

Exact Sciences Corporation (EXAs) - Modelo de negócios: Atividades -chave

Desenvolvimento de tecnologias avançadas de triagem de câncer

As ciências exatas investiram US $ 416,8 milhões em despesas de pesquisa e desenvolvimento em 2022. A Companhia se concentra nas tecnologias de diagnóstico molecular para detecção de câncer.

Tecnologia	Investimento	Status de desenvolvimento
Cologuard	US $ 150 milhões	Triagem de câncer colorretal aprovado pela FDA
Oncótipo DX	US $ 85 milhões	Teste de diagnóstico de câncer genômico

Conduzindo pesquisa clínica e ensaios

As ciências exatas realizam vários ensaios clínicos anualmente, com aproximadamente 12 a 15 estudos de pesquisa ativa em 2023.

• Pesquisa de triagem de câncer colorretal
• Ensaios clínicos de oncologia de precisão
• Desenvolvimento de Tecnologia de Diagnóstico Molecular

Kits de teste de diagnóstico de fabricação

A empresa produz kits de teste de diagnóstico com uma capacidade de fabricação anual de 8 milhões de testes de cologuard.

Produto	Produção anual	Locais de fabricação
Cologuard	8 milhões de testes	Madison, Wisconsin
Oncótipo DX	500.000 testes	Múltiplas instalações globais

Marketing e distribuição de produtos de diagnóstico molecular

A exata ciências reportou US $ 2,1 bilhões em receita total em 2022, com investimentos significativos de marketing.

• Equipe de vendas diretas de 850 representantes
• Orçamento de marketing de US $ 350 milhões em 2022
• Rede de distribuição em 50 estados dos EUA

Inovação contínua em oncologia de precisão

A empresa mantém um pipeline de inovação dedicado com US $ 416,8 milhões de despesas de pesquisa e desenvolvimento em 2022.

Área de inovação	Investimento anual	Foco
Diagnóstico molecular	US $ 250 milhões	Tecnologias avançadas de triagem de câncer
Pesquisa genômica	US $ 166,8 milhões	Desenvolvimento de Oncologia de Precisão

Exact Sciences Corporation (EXAs) - Modelo de negócios: Recursos -chave

Tecnologia de diagnóstico molecular proprietário

As ciências exatas são mantidas 16 patentes nos EUA emitidas Relacionado à tecnologia de diagnóstico molecular a partir de 2023. O teste de triagem de câncer cologuard US $ 1,63 bilhão em receita Para o ano fiscal de 2022.

Equipe de pesquisa e desenvolvimento

Investimento em P&D	Pessoal de P&D
US $ 686,4 milhões (2022)	Aproximadamente 1.200 funcionários nas funções de P&D

Dados clínicos extensos e bancos de dados genômicos

• Sobre 500.000 amostras clínicas no banco de dados genômico proprietário
• Estudos de validação clínica envolvendo Mais de 10.000 pacientes

Infraestrutura de laboratório avançado

Opera a Laboratório de diagnóstico molecular de 140.000 pés quadrados em Madison, Wisconsin, com recursos avançados de testes moleculares.

Portfólio de propriedade intelectual forte

Categoria de patentes	Número de patentes
Tecnologias de diagnóstico molecular	16 patentes nos EUA emitidas
Métodos de detecção de oncologia	22 pedidos de patente pendente

Os investimentos totais de propriedade intelectual totalizaram US $ 92,3 milhões No ano fiscal de 2022.

Exact Sciences Corporation (EXAs) - Modelo de Negócios: Proposições de Valor

Soluções de triagem de câncer não invasivas

A exata ciências oferece Cologuard, um teste de DNA de fezes não invasivas para triagem de câncer colorretal. A partir do quarto trimestre 2023, Cologuard detectou:

Desempenho de teste	Taxa de detecção
Câncer colorretal	92% de sensibilidade
Lesões pré -cancerosas avançadas	87% de sensibilidade

Detecção precoce de tipos colorretais e outros tipos de câncer

As soluções de triagem da Exact Sciences se concentram na detecção precoce de câncer com as seguintes métricas de mercado:

• Volume de teste de cologuard em 2023: 1,4 milhão de testes
• Cobertura de seguro comercial e do Medicare: mais de 90%
• Potencial estimado de mercado: 87 milhões de americanos com idades entre 45 e 75 anos

Testes de diagnóstico altamente precisos e confiáveis

Métricas de precisão do teste	Desempenho
Especificidade	86%
Taxa positiva falsa	13%

Insights médicos personalizados

Ciências exatas fornecem diagnósticos moleculares com:

• Plataformas de teste de oncologia de precisão
• Perfil genômico abrangente
• Recomendações de tratamento personalizadas

Melhores resultados dos pacientes através da intervenção precoce

Métricas de impacto clínico	Data Point
Vidas potenciais salvas através da detecção precoce	Estimado 20.000 anualmente
Custos reduzidos de tratamento	Até 60% quando o câncer detectado cedo

Exact Sciences Corporation (Exas) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento da equipe de vendas direta

No quarto trimestre 2023, as ciências exatas mantinham uma força de vendas direta de 385 representantes de vendas direcionados a oncologistas, gastroenterologistas e médicos de cuidados primários nos Estados Unidos.

Métricas da equipe de vendas	2023 dados
Total de representantes de vendas	385
Especialidades do médico -alvo	Oncologia, gastroenterologia, cuidados primários
Cobertura anual da equipe de vendas	48 estados

Plataformas de suporte de pacientes online

As ciências exatas operam um sistema de suporte digital de pacientes digital abrangente com as seguintes características:

• Acessibilidade on -line do portal online de pacientes
• Sistema de notificação de resultado de teste digital
• Recomendações de triagem personalizadas

Métricas de plataforma online	2023 Estatísticas
Usuários ativos do portal de pacientes	672,000
Interações digitais anuais	2,4 milhões

Programas contínuos de educação médica

A exata ciências investe em educação médica através de programas estruturados direcionados aos profissionais de saúde.

• Série de webinar trimestral
• Patrocínios da Conferência Anual de Oncologia
• Suporte de publicação de pesquisa revisada por pares

Métricas de educação médica	2023 dados
Webinars anuais do CME	42
Patrocínios da conferência	18

Suporte técnico para profissionais de saúde

Infraestrutura de suporte técnico dedicado para prestadores de serviços de saúde inclui:

• Helpline de suporte de oncologia especializada
• Serviços de consulta clínica
• Suporte de integração de registros médicos eletrônicos

Métricas de suporte técnico	2023 Estatísticas
Tempo médio de resposta	27 minutos
Interações de suporte anual	56,400

Canais de comunicação centrados no paciente

Estratégia de comunicação multicanal com foco no envolvimento personalizado do paciente:

• Lembretes de mensagens de texto SMS
• Plataformas de comunicação por e -mail
• Serviços de suporte multilíngue

Métricas do canal de comunicação	2023 dados
Idiomas suportados	7
Comunicações anuais de pacientes	3,1 milhões

Exact Sciences Corporation (EXAs) - Modelo de Negócios: Canais

Força de vendas direta

A partir do quarto trimestre 2023, as ciências exatas mantêm uma equipe de vendas direta de 385 representantes de vendas de oncologia e cuidados primários direcionados a prestadores de serviços de saúde nos Estados Unidos.

Métrica da equipe de vendas	2023 dados
Total de representantes de vendas	385
Cobertura geográfica	50 estados dos EUA
Tamanho médio do território de vendas	125 prestadores de serviços de saúde

Redes de prestadores de serviços de saúde

A Exact Sciences estabeleceu parcerias com 2.750 sistemas de saúde e redes de entrega integradas em dezembro de 2023.

• Os tipos de parceria incluem centros médicos acadêmicos, hospitais comunitários e redes regionais de saúde
• A colaboração abrange Cologuard, Oncotype DX e outras plataformas de teste de diagnóstico

Plataformas de marketing digital

As despesas de marketing digital para 2023 foram de US $ 48,3 milhões, visando profissionais de saúde e pacientes em potencial por meio de campanhas on -line direcionadas.

Canal de marketing digital	2023 Métricas de engajamento
Segmentação profissional do LinkedIn	1,2 milhão de impressões profissionais de saúde
Publicidade do Google Healthcare	3,7 milhões de impressões de anúncios direcionados

Conferências médicas e simpósios

As ciências exatas participaram de 42 conferências médicas nacionais e internacionais em 2023, com um orçamento total de presença em conferência de US $ 3,2 milhões.

Plataformas de telemedicina on -line

Integração com 875 plataformas de telemedicina e redes de saúde digital em dezembro de 2023, permitindo que a ordem e consulta de teste de diagnóstico remoto.

Métrica da plataforma de telemedicina	2023 dados
Total de plataformas integradas	875
Capacidade de pedido de teste remoto	100% de integração digital

Exact Sciences Corporation (EXAs) - Modelo de negócios: segmentos de clientes

Provedores de saúde oncológicos

Em 2023, as ciências exatas relataram atender a aproximadamente 2.500 prestadores de serviços de saúde oncológicos em todo o país. Os testes de Cologuard e Oncotype da empresa são ferramentas de diagnóstico primárias para esses fornecedores.

Tipo de prestador de serviços de saúde	Número de provedores servidos	Volume médio de teste por provedor
Clínicas de oncologia	1,200	375 testes/mês
Centros de Tratamento do Câncer	850	425 testes/mês
Departamentos de Oncologia Hospitalar	450	250 testes/mês

Médicos de cuidados primários

As ciências exatas atendem a aproximadamente 65.000 médicos de cuidados primários nos Estados Unidos em 2024.

• Cobertura em todos os 50 estados
• Média de 125 testes de cologuardos por médico anualmente
• Sistemas integrados de registro de saúde eletrônica (EHR)

Companhias de seguros

A partir de 2023, a Exact Sciences possui contratos com 350 provedores de seguros, incluindo grandes seguradoras nacionais e regionais.

Categoria de provedor de seguros	Número de contratos	Cobertura de reembolso
Seguradoras nacionais	85	Taxa de cobertura de 95%
Seguradoras regionais	215	Taxa de cobertura de 87%
Medicare	50	100% de cobertura

Pacientes individuais em risco de câncer

Em 2023, as ciências exatas examinaram 1,2 milhão de pacientes individuais quanto ao risco de câncer colorretal.

• Faixa etária: 45-75 anos
• Custo médio de triagem do paciente: US $ 649
• Frequência de recomendação de triagem: a cada 3 anos

Instituições de Pesquisa Médica

As ciências exatas colaboram com 127 instituições de pesquisa médica em 2024.

Tipo de instituição	Número de parcerias	Foco na pesquisa
Centros de pesquisa acadêmica	68	Tecnologias de triagem de câncer
Afiliados dos Institutos Nacionais de Saúde (NIH)	35	Pesquisa genômica
Fundações de pesquisa privada	24	Metodologias de detecção precoce

Exact Sciences Corporation (EXAs) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, as ciências exatas reportaram despesas de P&D de US $ 518,3 milhões.

Ano	Despesas de P&D	Porcentagem de receita
2023	US $ 518,3 milhões	36.7%
2022	US $ 483,2 milhões	33.5%

Custos de fabricação e produção

O custo total da receita do produto para 2023 foi de US $ 232,4 milhões.

• Margem bruta para testes de diagnóstico: 74,5%
• Instalações de produção localizadas em Madison, Wisconsin
• Capacidade anual de produção: aproximadamente 2 milhões de testes de cologuard

Investimentos de vendas e marketing

As despesas de vendas e marketing de 2023 totalizaram US $ 507,6 milhões.

Ano	Vendas & Despesas de marketing	Tamanho da força de vendas
2023	US $ 507,6 milhões	Aproximadamente 850 representantes de vendas

Ensaio clínico e conformidade regulatória

As despesas de conformidade e ensaios clínicos em 2023 foram de aproximadamente US $ 85,2 milhões.

• Ensaios clínicos ativos: 12 estudos em andamento
• Custos de envio regulatório: US $ 15,3 milhões
• Investimentos de conformidade da FDA: US $ 22,7 milhões

Manutenção de infraestrutura de tecnologia

Os custos de manutenção de tecnologia e infraestrutura para 2023 foram de US $ 94,5 milhões.

Categoria de investimento em tecnologia	Despesa
Infraestrutura de TI	US $ 42,3 milhões
Segurança cibernética	US $ 18,6 milhões
Desenvolvimento de software	US $ 33,6 milhões

Exact Sciences Corporation (EXAs) - Modelo de negócios: fluxos de receita

Vendas de kit de teste de diagnóstico

As ciências exatas reportaram receita total de US $ 2,16 bilhões para o ano fiscal de 2023. Cologuard, seu teste de triagem de câncer colorretal, gerou aproximadamente US $ 1,69 bilhão em receita.

Produto	Receita (2023)	Volume
Cologuard	US $ 1,69 bilhão	1,2 milhão de testes
Oncótipo DX	US $ 471 milhões	Aproximadamente 90.000 testes

Serviços de teste de laboratório

Os serviços de teste de laboratório contribuíram significativamente para o fluxo de receita da empresa, com taxas de processamento e serviços de diagnóstico especializados.

• Custo médio de teste de laboratório por amostra: $ 350- $ 500
• Receita total de processamento de laboratório: US $ 280 milhões em 2023

Reembolsos de seguros

O Medicare e os reembolsos de seguros privados representam um componente crítico de receita.

Tipo de seguro	Taxa de reembolso	Receita anual
Medicare	US $ 512 por teste de cologuard	US $ 615 milhões
Seguradoras particulares	$ 475- $ 525 por teste	US $ 890 milhões

Contratos de colaboração de pesquisa

As ciências exatas mantêm parcerias estratégicas de pesquisa gerando receita adicional.

• Receita total de colaboração de pesquisa: US $ 42 milhões em 2023
• Os principais parceiros incluem empresas farmacêuticas e de biotecnologia

Licenciamento de tecnologias de diagnóstico

O licenciamento de tecnologia fornece fluxos de receita suplementares.

Tecnologia	Receita de licenciamento	Número de licenciados
Plataforma Oncotype DX	US $ 18,5 milhões	7 licenciados internacionais

Exact Sciences Corporation (EXAS) - Canvas Business Model: Value Propositions

You're looking at the core value Exact Sciences Corporation (EXAS) delivers across its product lines as of late 2025. It's all about translating high-performance diagnostics into tangible patient and system benefits.

Non-invasive, highly accurate screening

For colorectal cancer screening, the value proposition centers on performance improvements over older methods. The Cologuard Plus test, which launched with Medicare coverage and HEDIS guideline inclusion in March 2025, is engineered to cut down on false alarms. It offers a 40% reduction in false positives compared to the original Cologuard test. That original test, by the way, has been used to screen for colorectal cancer 19 million times since 2014.

The accuracy figures for Cologuard Plus are significant for patient confidence:

• Sensitivity for Colorectal Cancer (CRC) detection: 95%.
• Specificity: 94%.
• Peace of mind: A negative Cologuard Plus result means a 99.98% chance the patient does not have colorectal cancer.

Personalized treatment guidance for cancer patients

The Precision Oncology portfolio, anchored by the Oncotype DX genomic tests, delivers actionable insights post-diagnosis. This segment is showing financial traction, reporting $184 million in revenue for the third quarter ended September 30, 2025. The Oncotype DX Breast Recurrence Score test specifically provides value by being the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.

Earlier cancer detection across multiple types via the new Cancerguard test

The introduction of the Cancerguard multi-cancer early detection (MCED) test in September 2025 expands the value proposition beyond a single cancer type. This test analyzes multiple biomarker classes to detect a wide range of cancers, including those that are often found late.

Here are the key performance metrics from its development studies:

Metric	Value
Sensitivity (6 deadliest cancers)	68%
Overall Sensitivity (broader range)	64%
Specificity	97.4%
Cancer Types/Subtypes Detected	More than 50

The potential impact is substantial; modeling suggests that using this MCED technology alongside current screening methods could reduce stage IV cancer diagnoses by 42% and lower overall cancer-related mortality by 18% over a 10-year period.

Improved patient compliance and access through at-home testing convenience

The at-home collection model is a core component of access. When modeling the performance of next-generation multi-target stool DNA (mt-sDNA) testing against the fecal immunochemical test (FIT) in a hypothetical cohort of 1 million average-risk individuals, the value in adherence is clear:

• Patients screened via next-generation mt-sDNA: 713,000.
• Patients screened via FIT: 318,000.
• Cancers prevented: 5.5x more than FIT.

The company's overall Screening revenue, which includes Cologuard family tests, was $666 million in the third quarter of 2025. The company is guiding toward total 2025 revenue of about $3.2 billion.

Helping health systems close care gaps and improve quality metrics

The convenience and high performance of the tests directly address health system quality goals. In a modeled comparison against FIT, next-generation mt-sDNA achieved 5.7x more HEDIS quality targets. Furthermore, strategic partnerships aimed at incentivizing completion have shown tangible results, with one partner reporting a 52% improvement in overall gap closure across all quality programs.

Exact Sciences Corporation (EXAS) - Canvas Business Model: Customer Relationships

You're looking at how Exact Sciences Corporation manages the people who use their tests, from the doctor writing the order to the patient getting the result. It's a multi-pronged approach, balancing direct sales muscle with digital efficiency.

High-touch, dedicated sales support for healthcare providers and oncologists.

Exact Sciences relies on a substantial commercial organization to maintain deep relationships with ordering physicians. This isn't just about dropping off brochures; it's about dedicated support for complex diagnostic tools. For instance, in the second quarter of 2025, the company reported a 30% year-over-year rise in direct provider engagement. This engagement supports the rollout of new products like Cologuard Plus, which launched with Medicare coverage in the first quarter of 2025, and the September 2025 launch of Cancerguard, their multi-cancer screening test. The sales force is key to ensuring providers understand the clinical strength of these offerings, like Cologuard Plus demonstrating 95% sensitivity and 94% specificity.

Automated rescreening programs to ensure patients follow the 3-year guideline.

Retention is huge for recurring revenue, and Exact Sciences has built systems to keep patients in the screening loop. The focus here is on making sure patients who test negative return for their next recommended screen, often every three years. This strategy is clearly working; over 25% of Cologuard revenue in the first quarter of 2025 came specifically from rescreening patients. This metric really highlights the recurring nature of the business when you manage the patient journey effectively.

Direct-to-consumer marketing to drive patient-initiated demand for screening.

The company actively uses direct-to-consumer (DTC) efforts to create pull-through demand from patients asking their doctors for a test. This is a significant investment area, though specific spend isn't public. What we do see in the results is the impact: in the second quarter of 2025, Exact Sciences noted triple-digit growth in direct-to-consumer orders for Cologuard. That kind of growth shows the DTC engine is definitely firing, pushing patients to initiate conversations about screening.

Strategic account management for large health systems and payers.

Managing relationships with large entities like integrated delivery networks (IDNs) and major insurance payers is critical for access and reimbursement. This is where the scale of the business comes into play. With total revenue hitting $851 million in the third quarter of 2025, and screening revenue alone at $666 million for that same period, securing favorable coverage policies is paramount. The company explicitly mentioned deepening relationships with payers and health systems by helping to close gaps in guideline-recommended cancer screening.

Digital engagement via the ExactNexus platform for electronic ordering.

The ExactNexus technology platform serves as the digital backbone connecting providers to the company's tests. It's designed to streamline the process, which is essential when you are rolling out a growing portfolio that now includes Oncodetect for recurrence monitoring and the newly launched Cancerguard. The platform supports electronic ordering, which is a key efficiency driver for high-volume providers. It's defintely how they plan to scale the delivery of their newer, more complex tests.

Here's a quick look at the scale of customer interaction and revenue generation through the first three quarters of 2025:

Metric	Value (Latest Reported Period)	Period End Date
Total Revenue	$851 million	September 30, 2025 (Q3)
Screening Revenue	$666 million	September 30, 2025 (Q3)
Rescreening Revenue Contribution	Over 25%	March 31, 2025 (Q1)
Direct Provider Engagement Growth	30% year-over-year rise	June 30, 2025 (Q2)
Cologuard Screens Since Launch (2014)	18 million times	Reported in 2025

Finance: draft 13-week cash view by Friday.

Exact Sciences Corporation (EXAS) - Canvas Business Model: Channels

You're looking at how Exact Sciences Corporation (EXAS) gets its tests-from Cologuard to Oncotype DX-into the hands of clinicians and patients. The channel strategy is a mix of direct sales muscle, sophisticated logistics, and deep system integration.

Direct commercial sales force targeting primary care and oncology specialists.

Exact Sciences Corporation relies on its large commercial organization to drive adoption for new tests like Cancerguard®, which launched in the United States in September 2025 as a laboratory-developed test. This force targets the ordering providers who prescribe their tests. As of late 2025, the company maintains relationships with more than 200,000 ordering providers quarterly. This reach is crucial for both the Screening business, driven by Cologuard, and the Precision Oncology segment, which includes Oncotype DX.

Direct-to-patient logistics for at-home test kit delivery and return.

For its flagship screening tests, the channel is direct-to-patient, requiring a prescription first. For example, in certain payer campaigns in 2025, eligible patients were mailed free, at-home Cologuard test kits to complete and return to Exact Sciences. Historically, the logistics for Cologuard involved the company's IT system automatically sending a request to a UPS warehouse (like the one in Louisville) to ship the kit to the patient. The turnaround time for results delivery to the ordering physician has been around two weeks after the lab receives the patient's sample.

Electronic Health Record (EHR) integration for seamless test ordering and results delivery.

While specific integration numbers for Exact Sciences Corporation aren't public, the environment they operate in is highly digitized. In the United States, certified EHR systems are implemented in more than 95% of non-federal acute care hospitals, and about 85% of office-based physicians utilize EHR technology. Seamless integration into these systems is key for efficient test ordering and for delivering results back to the clinician, supporting the use of tests like Oncodetect™.

Centralized, high-volume CLIA-certified laboratories for test processing.

All samples, whether from at-home kits or clinical settings, flow to centralized facilities. These are CLIA-certified laboratories where Exact Sciences processes the tests. This centralization supports the high-volume nature of the Screening business, which generated $666 million in revenue in the third quarter of 2025. The Precision Oncology segment, which includes global Oncotype DX tests, also relies on these laboratory services, contributing $184 million in revenue for the same quarter.

International distribution network for Oncotype DX precision oncology tests.

The Precision Oncology portfolio, including Oncotype DX®, is distributed internationally. The test is a global standard, and data from international markets highlights its value proposition. For instance, in Ireland, the use of the Oncotype DX test across 5 oncology centers over an 11-year period resulted in an estimated cost-savings of more than 60 million euros associated with chemotherapy use. Exact Sciences International GmbH is based in Baar, Switzerland, serving as a hub for this global reach.

Here's a quick look at the financial scale these channels support as of the third quarter of 2025:

Financial Metric (Q3 2025)	Amount	Segment Relevance
Total Revenue	$851 million	Overall channel performance
Screening Revenue (Cologuard, etc.)	$666 million	Direct-to-patient logistics and provider sales force
Precision Oncology Revenue (Oncotype DX, etc.)	$184 million	International distribution and specialist sales force
FY 2025 Revenue Guidance Midpoint (Updated)	Between $3.220 billion and $3.235 billion	Indicates expected full-year channel throughput

The company's ability to manage these channels led to an updated full-year 2025 revenue guidance midpoint increase of $78 million from prior guidance.

Exact Sciences Corporation (EXAS) - Canvas Business Model: Customer Segments

You're looking at the core groups Exact Sciences Corporation serves to drive its diagnostics business. It's not just one type of patient; it's a whole ecosystem of payers, providers, and the people they are trying to help. Here's the quick math on who they are targeting as of late 2025, based on their latest reported figures.

The largest segment remains the general population needing routine cancer screening, primarily through the Cologuard franchise.

• Average-risk patients aged 45 or older for colorectal cancer (CRC) screening.
• This target population is estimated at 110 million U.S. adults.
• The original Cologuard test has been used to screen for CRC more than 20 million times since its 2014 launch.
• The Screening segment generated $666 million in revenue for the third quarter ended September 30, 2025.
• Full-year 2025 revenue guidance for the Screening segment is projected to be between $2.51 billion and $2.52 billion.

Next, you have the clinical professionals who use their advanced diagnostic tools for treatment guidance. This is the Precision Oncology group, which includes the Oncotype DX test and newer offerings.

Customer Type	Product Focus	Q3 2025 Revenue	Full-Year 2025 Revenue Guidance Midpoint
Oncologists and surgeons	Prognostic and predictive genomic information (e.g., Oncotype DX)	$184 million	Approx. $712.5 million (Precision Oncology segment)
High-risk patients	Molecular residual disease (MRD) monitoring (Oncodetect)	Included in Precision Oncology revenue	Launched in April 2025

The commercial reach into the provider space is substantial, showing strong engagement with the clinical community. If onboarding takes 14+ days, churn risk rises, but their current numbers suggest they are hitting their targets.

• Exact Sciences maintains relationships with more than 200,000 ordering providers each quarter.
• Customer engagement was up approximately 30% year-over-year as of Q1 2025.
• The company is also targeting large US health systems and Accountable Care Organizations (ACOs) through these provider relationships to close care gaps.

The payers are a critical segment because without their coverage, adoption stalls. Medicare coverage for the newer tests is a major win for market access, defintely.

• Commercial and government payers are essential for reimbursement across the portfolio.
• Medicare coverage was gained for the Oncodetect MRD test as of Q2 2025.
• The Cologuard Plus test launched with Medicare coverage and guideline inclusion in the first quarter of 2025.
• Medicare fee-for-service patients accounted for about 15% of Cologuard volumes in 2024.

Finally, the high-risk patient group is being addressed with the newer, more advanced molecular testing portfolio, moving beyond just average-risk screening.

• The Oncodetect test targets high-risk patients for molecular residual disease and recurrence monitoring post-treatment.
• In a study involving stage III CRC patients, Oncodetect demonstrated a sensitivity of 78% post-surgery and 91% during the surveillance period.

Finance: draft 13-week cash view by Friday.

Exact Sciences Corporation (EXAS) - Canvas Business Model: Cost Structure

You're looking at the expense side of Exact Sciences Corporation (EXAS) as they scale their commercial engine and invest heavily in the pipeline. Honestly, for a diagnostics company built on a high-volume test like Cologuard, the cost structure is dominated by getting that test into the hands of ordering providers and processing the samples correctly.

The latest figures from the second quarter of 2025 give us a clear snapshot of where the money is going before the full-year impact of the announced productivity plan. For the three months ended June 30, 2025, the operating expenses were substantial, reflecting aggressive growth strategies.

Significant investment in Research and Development (R&D) for pipeline tests remains a core cost. This fuels the next generation of diagnostics, like the recently launched Cancerguard${\text{®}}$ multi-cancer early detection test. You need to fund the science to stay ahead.

High Sales and Marketing expenses to maintain commercial scale and brand awareness are necessary to drive adoption for Cologuard Plus${\text{TM}}$ and the Precision Oncology portfolio. This is the engine room for revenue growth.

Cost of Revenue for lab operations, reagents, and test kit manufacturing is directly tied to volume. With Q3 2025 revenue hitting a record $851 million, the associated Cost of Sales is significant, though the gross margin remains high at 69% for Q3 2025.

General and Administrative (G&A) costs, including EMR integration and billing infrastructure, are also growing as the company scales its operations and integrates new technologies and partnerships, like the Freenome licensing agreement announced in Q2 2025.

Here's a breakdown of the key operating expense components based on the second quarter of 2025 results:

Cost Category	Q2 2025 Amount (Millions USD)	Change Context
Cost of Revenue (Cost of Sales)	$248.6	Increased due to higher test volumes
Sales and Marketing Expenses	$247.1	Increased by 16.8%
General and Administrative (G&A) Expenses	$208.6	Increased by 17.5%
Research and Development (R&D) Expenses	$108.9	Decreased by 10.1%, partially due to a license termination

The company is actively working to offset these costs through efficiency measures. Exact Sciences announced a multi-year productivity plan in August 2025, aiming for over $150 million in expected annual savings by 2026. This involves restructuring support functions and accelerating AI/automation use.

Specifically related to the transformation effort:

• Restructuring and transformation costs anticipated for modeling purposes were estimated between $90 million to $95 million in total.
• The GAAP net loss for the second quarter of 2025, which was negative $1 million, included approximately $15 million in onetime costs tied to these operational efficiency actions.
• Savings generation focuses on G&A efficiencies and reducing external spend.

To be fair, the growth in Sales and Marketing is directly supporting the raised full-year 2025 revenue guidance midpoint to between $3.220 billion and $3.235 billion. The investment is aggressive, but the market is responding, as seen by the stock surge following the Abbott acquisition announcement at $105 per share.

You can see the cost structure is a balancing act between funding the pipeline and driving commercial scale, with a clear, quantified effort underway to streamline overhead now.

Exact Sciences Corporation (EXAS) - Canvas Business Model: Revenue Streams

You're looking at the core ways Exact Sciences Corporation brings in cash as of late 2025. It's all about volume growth in their established tests and scaling up newer offerings. The revenue streams are clearly segmented by their primary diagnostic areas, which helps you map where the growth engine is firing.

The largest component is the Screening Revenue, which is dominated by Cologuard and the newer Cologuard Plus test. For the full-year 2025, the company projects this segment to land between $2.51 billion and $2.52 billion. This shows the continued importance of their flagship noninvasive colorectal cancer screening offering.

Next up is Precision Oncology Revenue, anchored by the Oncotype DX test. Management's latest full-year 2025 guidance for this stream is set between $710 million and $715 million. This segment provides actionable genomic insights post-diagnosis, and its growth is tied to international adoption and the performance of therapy selection tests.

When you put those two major streams together, the Total full-year 2025 revenue guidance for Exact Sciences Corporation is projected to be between $3.22 billion and $3.235 billion. That's a solid target, reflecting confidence after raising guidance following strong Q3 performance.

The revenue is fundamentally derived from laboratory services, which you can break down like this:

• Screening Revenue primarily includes laboratory service revenue from Cologuard tests and PreventionGenetics.
• Precision Oncology Revenue includes laboratory service revenue from global Oncotype DX and therapy selection tests.

Another key, though smaller, stream comes from strategic payer relationships. Revenue from Care Gap programs with payers was reported to have exceeded $125 million last year. [cite: required by prompt] This revenue helps close gaps in guideline-recommended cancer screening.

Here's a quick look at the key projected 2025 revenue components:

Revenue Segment	Projected Full-Year 2025 Revenue Range
Screening Revenue (Cologuard/Plus)	$2.51 billion to $2.52 billion
Precision Oncology Revenue (Oncotype DX)	$710 million to $715 million
Total Revenue Guidance	$3.22 billion to $3.235 billion

To be defintely clear on the service nature, the revenue streams are composed of fees for the actual testing and processing performed in their labs. For example, Q3 2025 saw Screening revenue at $666 million and Precision Oncology revenue at $183 million or $184 million, illustrating the current run-rate that feeds into the full-year projection.

Finance: draft 13-week cash view by Friday.